These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 25894068)
1. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis. Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068 [TBL] [Abstract][Full Text] [Related]
2. Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs. Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Burden AM; Neef C; van den Bergh JP; Vestergaard P; de Vries F Calcif Tissue Int; 2015 Nov; 97(5):506-15. PubMed ID: 26184119 [TBL] [Abstract][Full Text] [Related]
3. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study. Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565 [TBL] [Abstract][Full Text] [Related]
4. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Driessen JH; van Onzenoort HA; Henry RM; Lalmohamed A; van den Bergh JP; Neef C; Leufkens HG; de Vries F Bone; 2014 Nov; 68():124-30. PubMed ID: 25093264 [TBL] [Abstract][Full Text] [Related]
5. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study. Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260 [TBL] [Abstract][Full Text] [Related]
6. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study. Werkman NCC; Driessen JHM; Stehouwer CDA; Vestergaard P; Schaper NC; van den Bergh JP; Nielen JTH Cardiovasc Diabetol; 2023 Jun; 22(1):160. PubMed ID: 37386427 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725 [TBL] [Abstract][Full Text] [Related]
8. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180 [TBL] [Abstract][Full Text] [Related]
9. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs. Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Neef C; van den Bergh J; Vestergaard P; de Vries F; Burden AM Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1017-25. PubMed ID: 26183226 [TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice. Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492 [TBL] [Abstract][Full Text] [Related]
11. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. Dao K; Shechtman S; Weber-Schoendorfer C; Diav-Citrin O; Murad RH; Berlin M; Hazan A; Richardson JL; Eleftheriou G; Rousson V; Diezi L; Haefliger D; Simões-Wüst AP; Addor MC; Baud D; Lamine F; Panchaud A; Buclin T; Girardin FR; Winterfeld U BMJ Open; 2024 Apr; 14(4):e083550. PubMed ID: 38663923 [TBL] [Abstract][Full Text] [Related]
12. Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists. Klonoff DC; Kim SH; Galindo RJ; Joseph JI; Garrett V; Gombar S; Aaron RE; Tian T; Kerr D Diabetes Obes Metab; 2024 Aug; 26(8):3128-3136. PubMed ID: 38742898 [TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947 [TBL] [Abstract][Full Text] [Related]
14. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Douros A; Filion KB; Yin H; Yu OH; Etminan M; Udell JA; Azoulay L Diabetes Care; 2018 Nov; 41(11):2330-2338. PubMed ID: 30150234 [TBL] [Abstract][Full Text] [Related]
15. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555 [TBL] [Abstract][Full Text] [Related]
16. Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes. Ciardullo S; Savaré L; Rea F; Perseghin G; Corrao G Diabetes Metab Res Rev; 2024 May; 40(4):e3791. PubMed ID: 38549238 [TBL] [Abstract][Full Text] [Related]